# Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.

> **NCT02033993** · PHASE2 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 199 (actual)

## Conditions studied

- Urothelial Cancer

## Interventions

- **DRUG:** Nab-Paclitaxel
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02033993
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-11
- **Primary completion:** 2018-05-03
- **Final completion:** 2020-10-28
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2023-08-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02033993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02033993, "Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02033993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*